E-biogen, a leading Korean bioinformatics company, strengthened its position in the biomedical R&D ecosystem by participating in multiple national and regional research projects. Utilizing its proprietary Software technology along with international platforms such as Lexogen and ArrayStar, the company advanced its capabilities in data analysis, multi-omics interpretation, and the development of Reagent & Kit solutions. Over the years, E-biogen focused on establishing a comprehensive analytical infrastructure essential for future precision medicine.

The company contributed to the development of a drug-resistant cancer research platform that integrated human-derived digital information with humanized immune disease-model animals. Through this project, E-biogen produced an R&D strategy report and proposed a collaborative model for new service structures within the research consortium.

E-biogen also led the development of rapid diagnostic kits capable of detecting 20 major narcotics simultaneously, along with a portable POCT device. This project accelerated the localization of multi-target diagnostic tools and strengthened national capabilities in field-level drug testing.

In infectious disease research, E-biogen supported the development of a PERK-IFN pathway–based HBV cccDNA inhibitor. The project aimed to identify and eliminate HBV variants to support therapeutic solutions for chronic hepatitis B patients. The company also participated in cannabis oil toxicity research, providing analytical data crucial for government policy regarding public safety and substance regulation.

Through various national projects, E-biogen contributed to tuberculosis vaccine marker development, scRNA-Seq cell counter innovation, and allergen LFA kit development for dust-mite detection. The company’s expertise in Software, combined with Lexogen and ArrayStar analytical platforms, played a significant role in these government-funded programs.

E-biogen additionally engaged in Network Living Cell Array development for drug screening, non-contact Microarrayer systems, and high-sensitivity microarray biochips—advancing automation and data precision in biological experimentation. The company’s extensive portfolio reflects its commitment to advancing biomedical research capabilities through integrated Reagent & Kit solutions.

E-biogen is a Korean bioinformatics and laboratory-tech company specializing in multi-omics analysis and data-driven research. With advanced Software platforms and partnerships with Lexogen and ArrayStar, the company has delivered high-quality bioinformatics services and developed various Reagent & Kit product lines. E-biogen continues to expand its role in precision medicine, diagnostics, drug discovery, environmental health, and advanced biotechnology research.